Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Oncogene Stories

2013-09-30 14:04:37

Weizmann Institute researchers discover that a “standoff” between a mutated gene and its normal counterpart keeps certain cancer cells alive What keeps leukemia cells alive almost forever, able to continue dividing endlessly and aggressively? New research at the Weizmann Institute suggests that, in around a quarter of all leukemias, the cancer cells rely on an internal “balance of terror” to keep going. When one version of a certain gene is mutated, it becomes a cancer-promoting...

2013-09-20 11:25:30

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene. "This is exciting because we've found what we believe to be a 'drugable target' here," says George Vasmatzis, Ph.D., a Mayo Clinic molecular...

2013-08-01 23:03:54

Findings reveal why patients with metabolism-related diseases are at higher risk for aggressive tumors. New York, NY (PRWEB) August 01, 2013 Blocking dietary sugar and its activity in tumor cells may reduce cancer risk and progression, according to researchers from the Icahn School of Medicine. The study, conducted in fruit flies and published in the journal Cell, provides insight as to why metabolism-related diseases such as diabetes or obesity are associated with certain types of...

2013-06-27 04:21:11

Presentation scheduled on June 27, 2013 at 9:20 a.m. ET in New York SAN DIEGO, June 27, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the OneMedForum Conference in New York on Thursday, June 27, 2013 at 9:20 a.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for one-on-one meetings during...

2013-06-03 04:21:20

Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York SAN DIEGO, June 3, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Jefferies 2013 Global Healthcare Conference in New York on Thursday, June 6, 2013 at 3:00 p.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for...

2013-05-08 11:34:58

A University of Colorado Cancer Center study recently published in the journal Cell Death & Disease shows that turning up a few microRNAs a little may offer as much anti-breast-cancer activity as turning up one microRNA a lot — and without the unwanted side effects. It´s a bit like the classic thought experiment known as the “tumor problem” formulated by Karl Dunker in 1945 and used frequently in the problem-solving literature: Imagine a person suffers from a...

2013-04-10 10:55:21

Understanding how oncogenes affect the body clock may help create better cancer treatments The Myc oncogene can disrupt the 24-hour internal rhythm in cancer cells. Postdoctoral fellow Brian Altman, PhD, and graduate student Annie Hsieh, MD, both from the in the lab of Chi Van Dang, MD, PhD, director of the Abramson Cancer Center, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, present their data in the "Metabolic Pathway Regulation in...

2013-04-02 12:32:57

Mutations in a protein called SPOP (speckle-type POZ protein) disarm it, allowing another protein called steroid receptor coactivator-3 (SRC-3) to encourage the proliferation and spread of prostate cancer cells, said researchers led by those at Baylor College of Medicine in a report that appears online in Proceedings of the National Academy of Sciences. Normally SPOP acts as a tumor suppressor gene by marking SRC-3 for destruction, said Dr. Nicholas Mitsiades, assistant professor of...

2013-03-12 08:30:29

Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA SAN DIEGO, March 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled to present a corporate overview at the 25(th) Annual Roth OC Growth Stock Conference at the Ritz-Carlton Laguna Nigel, in Dana Point, CA on Tuesday, March 19, 2013 at 12:00 p.m....

2013-02-12 04:20:51

SAN DIEGO, Feb. 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well and the Company expects to achieve analytical and clinical validation of the test in its CLIA laboratory in March 2013. When validation is completed, the test will be available to clinicians and their patients. In addition to the ongoing HPV validation studies, one clinical trial has been completed...